Protocol for a randomised, double-blind trial of a chronotherapeutic mHealth behaviour change intervention to optimise light exposure among older adults aged ≥60 years in Singapore (LightSPAN)

Resshaya Roobini Murukesu[1, 2, [0000-0002-0947-5817]]

Zahrah Alwi Alkaff[2, 1, [0009-0003-7344-3363]]

Denz Del Villar[1, 2, [0009-0000-5225-9987]]

Johannes Zauner[2, 4, [0000-0003-2171-4566]]

Manuel Spitschan[1, 2, 3, 4, [0000-0002-8572-9268]], *

[1] TUMCREATE, Singapore, Singapore
[2] TUM School of Medicine & Health, Department Health and Sport Sciences, Technical University of Munich, Munich, Germany
[3] TUM Institute for Advanced Study (TUM-IAS), Technical University of Munich, Garching, Germany
[4] Max Planck Institute for Biological Cybernetics, Max Planck Research Group Translational Sensory & Circadian Neuroscience, Tübingen, Germany

* Corresponding author: manuel.spitschan@tum.de

Abstract

Introduction: Suboptimal light exposure among older adults can exacerbate circadian disruption, sleep disturbances, mood disorders, cognitive decline and frailty. In urbanised environments like Singapore, older adults are particularly vulnerable due to lifestyle and built environment constraints. The LightSPAN study evaluates a chronotherapeutic mobile health (mHealth) behaviour change intervention, delivered via the LightUP app, designed to optimise light exposure patterns and support healthy ageing.

Methods and analysis: The main trial is a community-based, double-blind, parallel-group randomised controlled trial involving approximately 90 community-dwelling older adults (≥60 years) recruited through Active Ageing Centres in Singapore. Participants will be randomised using a secure web-based system with stratification by age, sex and recruitment site to receive either the active LightUP app with behaviour change features (goal setting, self-monitoring, personalised feedback) or a placebo version without these features. The primary outcome is daily time above 250 lx melanopic equivalent daylight illuminance (melanopic EDI) during daytime, measured with the ActLumus light logger across baseline, intervention and follow-up periods. Secondary outcomes include sleep parameters and circadian rest-activity rhythms (Garmin Vivosmart 5 and sleep diary), sleep quality (PSQI), mood (BMIS, SIMS, VAMS), cognition (NIH Toolbox tests including Rey Auditory Verbal Learning), frailty (Fried's phenotype), physical activity (PASE, Garmin), body composition (bioimpedance) and vitamin D status (25(OH)D from dried blood spot. The usability and acceptability of the LightUP app and wearable devices will also be assessed. Analyses will follow the intention-to-treat principle, supplemented by per-protocol analyses. Generalized linear mixed models will be used for repeated measures, with multiple imputation for missing data and exploratory Bayesian analyses. All analyses will be pre-registered on the Open Science Framework and de-identified datasets and code will be openly shared under a CC-BY license.

47 **Ethics and dissemination:** Ethics approval obtained from Parkway Independent Ethics
48 Committee with reference number PIEC/2024/041.

49 **Registration:** This study is registered at the ISRCTN (ISRCTN12391932,
50 https://doi.org/10.1186/ISRCTN12391932).

51 **Keywords**: digital health, older adults, chronobiology, behaviour change, light exposure

Strengths and Limitations

Strengths

- Novelty: first digital behavioural intervention specifically targeting light exposure as a modifiable and lifestyle-based preventive health and health promotion strategy in older adults.
- Rigorous design: double-blind randomised controlled trial with allocation concealment and balancing by sex, age and site, reducing bias and improving internal validity.
- Multi-modal assessment: use of objective (ActLumus light logger, Garmin Vivosmart 5) and validated subjective measures (e.g., PSQI, MoCA, NIH Toolbox) to capture comprehensive outcomes.
- Pilot and feasibility phase: inclusion of a pilot trial to refine procedures, reduce implementation risks and ensure feasibility before the main trial.
- Community-based recruitment: implementation through Lions Befrienders' Active Ageing Centres enhances ecological validity and real-world applicability.

Limitations

- Technology burden: older participants may face challenges with device wear, data syncing and app usage, potentially affecting adherence and completeness.
- Sample size assumptions: based on a Malaysian dataset, which may not fully capture variability in the Singaporean older adult population.
- Attrition risk: despite over-recruitment, dropout related to digital literacy and participant burden may reduce statistical power.
- Restricted generalisability: exclusion of individuals with cognitive impairment, ocular disease, or depressive symptoms may limit applicability to the wider older adult population.
- Reliance on self-report: mood and sleep diaries depend on participant entries, which may introduce recall bias or missing data.

Introduction

Background and rationale (SPIRIT 2025 9a)

Light is the dominant zeitgeber for human circadian rhythms, regulating sleep-wake timing, physiology and health[1]. Inadequate or poorly timed light exposure is associated with circadian disruption, impaired sleep, mood disturbances, cognitive decline and metabolic dysregulation[2-4]. Older adults are particularly vulnerable, as ageing is associated with reduced ocular light transmission, decreased outdoor activity and comorbidities that reduce daily light exposure[5-11].

Evidence suggests that improving light exposure can stabilise circadian rhythms and support sleep and wellbeing in ageing populations, including patients with dementia[12-14]. However, conventional interventions such as bright light therapy boxes, while effective in controlled trials, often face barriers to real-world use: they require active engagement, can be costly and show low adherence[15]. Recent work has highlighted the need for scalable, accessible and user-friendly strategies that deliver sustained behavioural change in light exposure[16].

Mobile health (mHealth) interventions offer a promising alternative. Smartphones can provide personalised feedback, encourage self-monitoring and deliver behaviour change techniques. While mHealth approaches have been widely studied for physical activity, diet and chronic disease management, little evidence exists on their role in modifying light exposure behaviour[16 17]. Integrating wearable light sensors with mHealth interventions could provide a scalable, data-driven solution to optimise daily light exposure in naturalistic settings.

Explanation for choice of comparator (SPIRIT 2025 9b)

We selected a placebo version of the LightUP app as the comparator to ensure blinding and to isolate the specific effects of the behavioural intervention. Both groups use the same wearable devices (light logger and activity tracker) to monitor light, activity and sleep, but only the intervention group receives active features including personalised feedback, prompts and education. This design allows us to control for potential confounding effects of self-monitoring and study participation while testing whether the behavioural features of the LightUP app confer additional benefit. As no standard of care currently exists for promoting light exposure in community-dwelling older adults, a placebo app was chosen over usual care to enhance methodological rigour.

Objectives (SPIRIT 2025 10)

The general objective of this protocol is to evaluate the effectiveness of the LightSPAN mHealth intervention in optimising light exposure behaviour and improving physiological outcomes among community-dwelling older adults in Singapore.

The specific objectives are:

1. To assess the effectiveness of the LightUP app in optimising daily light exposure patterns

2. To determine whether the intervention improves circadian rest-activity rhythms, sleep quantity and quality, mood and cognitive performance

3. To evaluate effects on frailty status, physical activity, body composition and vitamin D status

4. To examine feasibility, acceptability, usability and user satisfaction of the intervention

5. To explore the acceptability and user experience of the ActLumus light logger device

Methods

Patient and public involvement (SPIRIT 11)

Members of the public were involved in the design and planning of this study. Feedback from older adults recruited through community partners in Singapore helped to shape the study aims, ensure the intervention content was accessible and adapt the study procedures for cultural and linguistic appropriateness. Input was obtained on the usability of the mobile health app, the acceptability of wearing devices (light logger and activity tracker) and the burden of questionnaires. Community organisations and social service agencies such as Lions Befrienders also contributed to the development of recruitment strategies at Active Ageing Centres and will assist in the dissemination of study findings to participants and the wider community. The process of obtaining feedback from older adults and community partners has been reported in the published co-design protocol[18]. Patients and public representatives were not involved in drafting the present protocol.

Trial design (SPIRIT 12)

The LightSPAN trial is a randomised, double-blind, parallel-group, placebo-controlled trial conducted in community-dwelling older adults in Singapore. After a 4-week baseline monitoring period, eligible participants are randomised in a 1:1 ratio to either the intervention arm (LightUP app with active behavioural features) or the control arm (placebo version of the app without behavioural features).

Randomisation is performed using computer-generated block randomisation stratified by age, sex and recruitment location to ensure balance across groups. Study staff conducting assessments are blinded to group allocation. The intervention lasts 12 weeks, followed by a 12-week post-intervention follow-up period, including 2 weeks of monitoring.

The trial design therefore allows for evaluation of both short-term (during intervention) and sustained (post-intervention) effects on light exposure, circadian rhythms, sleep, mood, cognition, frailty, physical activity and vitamin D status.

Trial setting (SPIRIT 13)

The trial is conducted in Singapore at five Lions Befrienders Active Ageing Centres, which serve as community hubs for older adults. Recruitment is community-based, targeting older adults aged 60 years and above who are living independently. All assessments and app-based interventions are coordinated from TUMCREATE Ltd. Participants are expected to attend assessments at the study centres, while the intervention itself is delivered in participants' home environments using smartphones and wearable devices. The planned sample size is 90 participants.

Eligibility criteria (SPIRIT 14a, 14b)

Participants are community-dwelling older adults aged 60 years and above, residing in Singapore. To be eligible, individuals must be capable of independent mobility, with or without assistive devices and demonstrate functional independence as assessed by the Lawton Instrumental Activities of Daily Living (IADL) scale[19], with a score greater than 8 for females and greater than 5 for males. Participants are required to own a smartphone, be proficient in English reading and communication and not be currently enrolled in another mobile health interventional study.Exclusion criteria include the presence of cognitive impairment, defined as a Montreal Cognitive Assessment (MoCA)[20] score below 26 after education adjustment, or depressive symptoms, defined as a score greater than 6 on the short form of the Geriatric Depression Scale (GDS)[21]. Individuals with significant physical impairments and/or medical diagnoses that interfere with daily activities, severe terminal illness, or psychiatric conditions affecting daily function are also excluded. Participants with visual impairment, diagnosed eye diseases, ocular abnormalities (as assessed by a licensed optometrist), or uncorrected hearing impairment are not eligible.

Eligibility for study sites is restricted to community-based active ageing centres partnered with the study, which provide accessible facilities for recruitment and assessment. Personnel involved in delivering the intervention and conducting assessments are trained research staff with specific expertise in cognitive, mood, frailty and physical performance testing, ensuring consistency and quality in data collection.

Intervention and comparator (SPIRIT 15a-d)

Intervention and comparator

The experimental intervention is the LightUP mobile health application, used for 12 weeks following a 4-week baseline monitoring phase. The app delivers behaviour change techniques including personalised feedback, self-monitoring, goal setting and educational messages about healthy light exposure. Data from a pendant-worn ActLumus light logger and a Garmin Vivosmart 5 activity tracker are integrated into the app to tailor recommendations. Participants receive a mid-intervention drop-in session to support sustained engagement.

The comparator is a placebo version of the LightUP app, which collects light, sleep and mood data but does not provide feedback, prompts, or goal-setting features. Participants in the comparator group also wear the ActLumus light logger and Garmin device. This ensures equivalent monitoring between groups and isolates the behavioural features of the intervention. Following the 12-week intervention, both groups enter a 12-week follow-up phase, which includes 2 weeks of extended monitoring.

Criteria for discontinuing or modifying allocated interventions

Participants may withdraw from the allocated intervention at any time, either at their own request or if adverse events, discomfort, or technical difficulties occur. In such cases, participants are invited to continue follow-up assessments unless they withdraw consent entirely. The intervention protocol is standardised and no modifications to the app are anticipated beyond its automated, data-driven feedback features. All instances of discontinuation or protocol deviation will be recorded.

Strategies to improve adherence

Adherence is supported through multiple strategies. The LightUP app incorporates reminders, progress-tracking features and personalised prompts to encourage consistent use. Research staff provide technical support for device setup, troubleshooting and ongoing use. A mid-intervention drop-in session is conducted to maintain engagement. Adherence is monitored through app usage logs, wearable device data and completion of scheduled assessments.

Concomitant care

Participants are permitted to continue all aspects of their usual medical care, daily routines and lifestyle activities throughout the trial. However, concurrent participation in other mobile health intervention studies or trials targeting circadian rest-activity rhythms, sleep, mood, cognition, frailty, physical function, or vitamin D is not permitted, to avoid contamination and ensure that behavioural changes can be attributed to the LightUP app. All relevant changes in health status or treatments during the study will be documented.

Outcomes (SPIRIT 16)

Primary outcome

The primary outcome is the effectiveness of the LightUP app in improving light exposure behaviour in older adults. This will be assessed using data from the ActLumus wearable light logger (ActLumus, Condor Instruments; São Paolo, Brazil)across the 4-week baseline, the 12-week intervention and the 2-week follow-up monitoring period. The primary analysis metric is the mean daily time (minutes per day) spent above 250 lx melanopic equivalent daylight illuminance (melanopic EDI) during daytime hours. Changes will be calculated relative to baseline and both short-term effects (during the 12-week intervention) and longer-term effects (during follow-up) will be examined using generalized linear mixed models.

Secondary outcomes

Secondary outcomes span multiple domains:

- **Sleep.** *Quantity and quality*: total sleep time, sleep efficiency, sleep onset latency and wake after sleep onset, measured via Garmin Vivosmart 5 (Garmin Ltd., Olathe, KS, USA) actigraphy and sleep diaries throughout the study. *Subjective quality*: assessed using the Pittsburgh Sleep Quality Index (PSQI)[22] at weeks 4 (baseline), 10 (midpoint), 16 (endpoint) and 28 (follow-up).
- **Circadian rhythms**. Interdaily stability, intradaily variability and relative amplitude of rest-activity cycles, measured continuously with Garmin data across the study period.
- **Mood**. Brief Mood Introspection Scale (BMIS)[23] at baseline, midpoint, endpoint and follow-up. Daily Single-Item Mood Scale (SIMS)[24]. Weekly Visual Analogue Mood Scale (VAMS) during the intervention.
- **Cognition**. NIH Toolbox battery[25] at baseline, midpoint, endpoint and follow-up, including the Dimensional Change Card Sort, Flanker Inhibitory Control and Attention, Oral Symbol Digit, Picture Sequence Memory, Rey Auditory Verbal Learning and Pattern Comparison Processing Speed tests.
- **Frailty and physical activity**. Frailty measured using standard criteria (weight loss, exhaustion, low activity via PASE, slowness via 5-metre walk and grip strength[26]).

Physical activity (daily step count, sedentary behaviour, moderate-to-vigorous activity) via Garmin. .

- **Body composition.** Weight, body fat percentage, muscle mass, bone mass and body mass index (BMI), assessed at baseline, midpoint, endpoint and follow-up using a bioelectrical impedance analysis (BIA) machine (TANITA DC-430MA, Tanita Corporation, Tokyo, Japan).
- **Vitamin D status.** Vitamin D status will be assessed from dried blood spot samples at the same timepoints. 25-hydroxyvitamin D [25(OH)D] concentrations will be measured with a dried blood spot test kit (Vitamin D Test, NeoVos by SureScreen Health, Newcastle Upon Tyne, United Kingdom).
- **Feasibility, usability and acceptability**. Usability of the LightUP app measured by the mHealth App Usability Questionnaire (MAUQ)[27] at endpoint. Acceptability of the app and wearable devices assessed using an adapted Technology Acceptance Model (TAM) questionnaire[28] at endpoint. Qualitative feedback on participant experience, app usage behaviour and overall acceptability of the app will be obtained through a focus group discussion at endpoint assessment.

Time points for analysis

Primary and secondary outcomes will be analysed at baseline (week 4), mid-intervention (week 10), end of intervention (week 16) and follow-up (week 28), depending on the measure. Continuous monitoring outcomes (e.g. light exposure, actigraphy, mood diaries) will be aggregated into daily or weekly metrics as appropriate.

Harms (SPIRIT 17)

The LightSPAN trial is considered minimal risk, as the intervention involves the use of a mobile health application and wearable monitoring devices. There are no known serious harms associated with these technologies. Possible risks include minor discomfort from wearing the ActLumus light logger or Garmin Vivosmart 5 activity tracker. These risks are considered low and are comparable to wearing commercially available wearable devices. No invasive procedures are involved except for dried blood spot collection for vitamin D analysis, which may cause minor discomfort.

Systematically assessed harms

Participants excluded following ocular health screening will receive a referral letter outlining the findings and recommending follow-up with an appropriate healthcare provider or specialist.

Non-systematically assessed harms

Participants are encouraged to report any problems or adverse experiences spontaneously to the study team throughout the trial. Reports will be collected via phone, email, or in person during centre visits.

Coding and grading of harms

All adverse events will be documented and coded by study staff according to severity (mild, moderate, severe) and relatedness to the intervention (unrelated, possibly related, probably related). Coding will be performed by personnel blinded to group allocation. No formal clinical grading system is planned, as no serious medical harms are anticipated.

Grouping of harms and reporting

Harms will be grouped by seriousness (serious versus non-serious), severity and type (e.g., device-related discomfort, app-related difficulties). Any adverse events leading to discontinuation of the intervention will be recorded separately. If a serious adverse event is reported, it will be immediately reviewed by the Principal Investigator and reported to the Parkway Independent Ethics Committee (PIEC), in line with ethical approval requirements.

Participant timeline (SPIRIT 18)

Following eligibility screening and informed consent, participants undergo a 4-week baseline monitoring period (weeks 1-4). During this period, they wear the ActLumus light logger and Garmin Vivosmart 5 activity tracker . Following the baseline monitoring period, participants undergo baseline assessments (week 4) and are randomised in a 1:1 ratio to either the intervention or comparator arm.

The intervention phase lasts 12 weeks (weeks 4-16). Participants in the intervention group use the LightUP mobile health app, which delivers personalised feedback, education and goal setting, while participants in the comparator group use the placebo version of the app that records but does not provide feedback. Both groups continue to wear the ActLumus logger and Garmin device throughout this period. An additional drop-in session is delivered at week 10 to reinforce adherence.

A follow-up period of 12 weeks (weeks 17-28) follows the intervention. During this time, participants no longer use the app but continue their usual monitoring and assessments. The follow-up includes a 2-week monitoring phase with both the ActLumus and Garmin devices to assess sustained changes in light exposure, sleep and circadian rhythms.

Assessments are scheduled at four key time points:

- **Week 4 (baseline assessment):** sleep quality (PSQI), mood (BMIS), cognition (NIH Toolbox), frailty (five criteria), physical activity (PASE), body composition, vitamin D (25(OH)D).

- **Week 10 (midpoint):** interim assessments of sleep, mood, cognition, frailty, physical activity, body composition and vitamin D.

- **Week 16 (endpoint):** repeat assessments including usability (MAUQ),acceptability (TAM) questionnaires and qualitative post-trial discussion.

- **Week 28 (follow-up):** repeat full assessments, including 2 weeks of device-based monitoring.

For each participant, the study timeline is as follows:

Week	Block
1	Enrolment, screening and consent
1-4	Baseline observation period

4	Baseline assessment (BL)
4-16	Intervention period
10	Midpoint assessment (MP)
16	Endpoint assessment (EP) and post-trial discussion
	Follow-up period
26-28	Follow-up observation period
28	Follow up assessment (FU)

Sample size (SPIRIT 19)

Based on power calculations conducted using existing light exposure data, we estimate that a sample size of 25 participants per group (i.e., 50 participants in total) is sufficient to detect a 20% change in light exposure metrics with 80% power, assuming a standard deviation of 0.2 and a two-sided alpha of 0.05.

These calculations were based on an existing dataset from Malaysia, derived from a previous study comparing light exposure patterns in Switzerland and Malaysia [3]. This dataset is the closest available approximation to our target study population in terms of geographic and lifestyle similarities.

The power analysis focused on three light exposure metrics derived from the Malaysia dataset:

- Time spent above 1000 lx melanopic equivalent daylight illuminance (EDI) during the daytime
- Time spent above 250 lx melanopic EDI during the daytime
- Time spent below 10 lx melanopic EDI in the evening

A 20% relative change in each of these metrics corresponds to approximately:

- ~9 minutes/day increase above 1000 lx melanopic EDI
- ~20 minutes/day increase above 250 lx melanopic EDI
- ~30 minutes/day reduction below 10 lx melanopic EDI in the evening

However, to account for:

- Additional outcome domains such as sleep, mood and cognitive function, which may show greater variability or require larger sample sizes to detect meaningful effects
- Considering the intensive nature of the trial and to effectively account for potential dropouts, an expected attrition rate of 25-30%, which is typical in studies involving older adults
- The need for more robust, generalizable results across a wider population

We plan to recruit a total of 90 participants (45 per group). This allows for approximately 63-68 participants to complete the study, corresponding to 31-34 participants per group, even after accounting for attrition. The recruitment strategy is

guided by findings from similar mHealth interventions involving older adults, where dropout rates tend to be higher due to factors such as technology challenges, health status and varying levels of digital literacy. Studies in this demographic[29 30] have demonstrated that over-recruiting by approximately 25-30% is a best practice to ensure adequate sample sizes for meaningful data analysis. By aiming to retain at least 90 participants, we align with research standards that suggest this number is sufficient for exploratory analysis of the intervention's effectiveness and feasibility.

Recruitment (SPIRIT 20)

Participants will be recruited from five Lions Befrienders Active Ageing Centres across Singapore, which provide access to a diverse population of community-dwelling older adults. Recruitment strategies include on-site information sessions, flyers and outreach via community staff. Interested individuals will be screened for eligibility by trained research staff.

Enrolment will continue until the target sample size of 90 participants is reached. Research staff will maintain regular contact with participants during the baseline monitoring period to encourage retention and to address technical issues promptly. The collaboration with established community organisations is expected to facilitate efficient recruitment and reduce participant burden.

Recruitment has started on 18 August 2025 and the trial will continue until 17 June 2026.

Sequence generation (SPIRIT 21a, 21b)

Randomisation will be conducted using computer-generated block randomisation with the R package *blockTools*, stratified by age, sex and recruitment location to ensure balanced allocation across key demographic variables. Study staff responsible for conducting assessments will be blinded to group assignment to minimize bias.

Allocation concealment mechanism (SPIRIT 22)

To guarantee allocation concealment, the allocation sequence will be securely implemented by a research team member who is not in direct contact with the participants.

Implementation (SPIRIT 23)

Participant enrolment is conducted by trained research staff at the partner Active Ageing Centres. Group assignment is performed only after eligibility confirmation and completion of baseline assessments. The random allocation sequence is generated by an independent statistician and stored within a secure, central, web-based randomisation module managed by the data management team. Enrolling staff request assignment through this system; the system releases the allocation only at the point of randomisation. Personnel responsible for enrolment and those delivering study procedures have no access to the randomisation list or block details. The master sequence file is access-restricted (statistician and data manager only) and kept on an encrypted server with audit logs.

Blinding (SPIRIT 24a-c)

Who is blinded

Strict double-blind procedures will be maintained throughout the study. Both participants and researchers will be blinded to the group assignments to prevent bias. Any technical or logistical queries regarding the use of light loggers and the LightUP app will be addressed by a designated technical support team that is also blinded to the group assignments. This arrangement will reduce the risk of unintentional unblinding through routine interactions and ensure that study integrity is preserved.

How blinding is achieved and maintained

Blinding is maintained by using two apps with identical appearance, naming, iconography, onboarding flow and data entry screens. Both apps collect the same light, sleep and mood data and interact identically with the ActLumus logger and Garmin tracker; only the intervention app contains the active behaviour-change features (feedback, goals, prompts), which are implemented via server-side logic not visible to participants or assessors. App store/package identifiers and version numbers are masked in participant-facing materials; installation is performed via a study link that deploys the correct configuration automatically. Staff who perform outcome assessments have no role in app provisioning. To evaluate blinding integrity, participants and assessors will be asked at endpoint to guess the assigned group and rate their confidence.

Unblinding procedures

Unblinding will only be conducted in exceptional cases where it is necessary for safety or technical reasons:

- Medical emergencies: In the event of a medical emergency where knowledge of the group assignment is essential for participant safety, the principal investigator (PI) will be notified. If deemed necessary, the PI will authorize a designated unmasked study personnel to access the randomization code by referring to the secure manual randomization list.

- Technical issues: Should significant technical issues arise with the LightUP app or light loggers, unblinding may be required to resolve the problem. Only the technical team, authorized by the PI, will be granted access to the randomization code to address the issue. Participants will remain blinded throughout this process and no data will be compromised as a result of technical unblinding.

Data collection methods (SPIRIT 25a-25b)

Plans for assessment and collection of trial data

Outcome data will be collected using a combination of wearable devices, validated questionnaires, cognitive tests and clinical assessments as outlined in the Outcomes section of this protocol. Light exposure is measured continuously using the ActLumus pendant logger, while rest-activity cycles, sleep and physical activity are recorded using the Garmin Vivosmart 5 tracker. Validated self-report instruments include the Pittsburgh Sleep Quality Index (PSQI), Brief Mood Introspection Scale (BMIS), Visual Analogue Mood

Scale (VAMS), NIH Toolbox cognitive tests and the Physical Activity Scale for the Elderly (PASE). Frailty measures include grip strength, gait speed, weight loss, exhaustion and activity level. Body composition is assessed using a body impedance analyser and vitamin D is measured using dried blood spot analysis. Usability and acceptability of the intervention are assessed using the mHealth App Usability Questionnaire (MAUQ) and an adapted Technology Acceptance Model (TAM) survey.

To ensure quality, all assessors are trained and certified in administering the questionnaires and performance-based measures. Standard operating procedures are in place for device calibration, biosample handling and data transfer. Data is collected electronically using secure, tablet-based entry systems, with automatic checks for out-of-range or missing values.

Plans to promote participant retention and follow-up

Retention strategies include regular check-ins with participants, technical support for device use and reminder notifications via the app in both trial arms. Participants who discontinue the intervention will still be invited to complete outcome assessments at scheduled visits. Reasons for non-adherence (e.g. device discomfort, loss of interest) or non-retention (e.g. withdrawal, loss to follow-up) will be systematically documented.

Data management (SPIRIT 26)

All study data will be entered into a secure database hosted at TUMCREATE. Data entry is performed electronically, with range checks, mandatory fields and double verification for critical variables. Data from wearable devices are automatically synchronised with the study server through encrypted transfer. Biosample results are entered by laboratory staff following validation.

Data security is ensured by password-protected accounts, role-based access controls and daily backups. The final locked dataset will be archived for at least 10 years on secure institutional servers.

Statistical methods (SPIRIT 27a-d)

Primary and secondary analyses

The analyses will focus on quantitative differences in sleep quality, cognition, and mood at assessment time points: baseline (BL), midpoint (MP), endpoint (EP), and follow-up (FU). The primary hypothesis is that differences between BL, MP and EP will vary depending on group assignment. These differences will be examined using generalized linear mixed models (GLMMs), with group assignment included as a fixed factor and participant as a random factor.

Exploratory analyses will incorporate BL MP, EP, and FU as covariates or as additional outcomes to characterise temporal patterns. Statistical significance will be assessed using a two-sided alpha threshold of 0.05. In addition, Bayesian analyses may be conducted, providing posterior estimates with credible intervals as a complementary approach.

Light exposure patterns will be analysed per individual, with the primary metric being daily time above threshold (TAT) in minutes, using a 250 lx melanopic equivalent daylight illuminance (melanopic EDI) threshold. Daily TAT values will be entered into GLMMs including group assignment and day-in-trial as factors, enabling assessment of both

overall group differences and trajectories over time. Inferential analysis of TAT in another study (reference to Malaysia/Switzerland paper) has shown that a Poisson error distribution is a good fit for mixed-effect analyses of this metric. This distribution will thus be used as a baseline error family in all analysis with TAT as the dependent variable. Model diagnostics include visual checks for homoscedasticity, normality of residuals and random effects, and their location at zero.

Additional exploratory analyses maybe be conducted and pre-registered on the Open Science Framework.

Statistical analyses will be conducted using R. Particular R packages that are planned to be used, among others, include *LightLogR*[31] for processing and calculating light data and variables, and *tidyverse*[32] for a stringent, tidy analysis framework

p-values will be calculated through a likelihood ratio test of models with and without a parameter in question. For the statistical tests, unstandardised effect sizes are reported as a result of the final models, i.e., beta-coefficients. A false-discovery-rate correction[33] will be applied within every dedicated branch of the analysis, based on the number of models/tests performed within that specific branch.

The full model in Wilkinson notation will follow this build:

$$\text{Outcome variable} \sim \text{group} * \text{assessment block} + \text{sex} + \text{age} + (\text{assessment block}|\text{participant})$$

While sex and age interaction effects are possible with the intervention, computational stability and sample size likely do not allow for the inclusion of these interactions. Random effects for participants will include both random slopes by assessment block, and random intercepts, and only be reduced to random intercepts in specific cases[34].

Continuously collected measurements, like light exposure, might further be explored non-linearly through generalized additive mixed models (GAMMs)[35], which have been shown to be a good fit for personal light exposure data[36].

Analysis population

Analyses will follow the intention-to-treat principle, including all randomised participants in their assigned groups. A per-protocol sensitivity analysis will be performed including only participants with high adherence (≥80% app engagement and valid device wear).

Handling of missing data

Missing outcome data will be examined for patterns and assumed to be missing at random. Mixed-effects models inherently accommodate unbalanced repeated measures. For questionnaire outcomes, multiple imputation using chained equations will be considered. Sensitivity analyses (best-case/worst-case) will be conducted to assess robustness of findings. Missing or irregular data from the wearable light loggers will not be imputed. Irregular data may be regularized to a consistent time series of data within a participant and collection period. Participant days missing more than 2 hours of data will be excluded from metric calculations and thus further analysis. Biller et al. (Malaysia/Switzerland) found that 6 hours of missing data led to non-significant differences in a month-long data collection effort per participant. As the follow-up period only contains 2 weeks of data collection, we choose this more conservative threshold.

Additional analyse

Additional exploratory analyses will be pre-registered on the Open Science Framework prior to execution, ensuring transparency.

Data monitoring committee (SPIRIT 28a-28b)

Composition and role

Given the minimal-risk nature of the intervention (digital health app and wearable devices), no independent Data Monitoring Committee (DMC) will be established. Trial oversight will be managed by the study's Steering Committee, which includes investigators from TUMCREATE and collaborating institutions. The Steering Committee meets monthly to review recruitment, adherence, data quality and any adverse events.

Interim analyses and stopping guidelines

No formal interim analyses are planned. Stopping criteria will be limited to safety concerns identified by the Steering Committee (e.g., unforeseen adverse events related to device use). Any decision to terminate or modify the trial will rest with the Principal Investigator in consultation with the Steering Committee and the Institutional Review Board (IRB).

Trial monitoring (SPIRIT 29)

Trial conduct will be monitored by the institutional research governance office, which will conduct regular remote monitoring of recruitment, consent forms and data quality. Monitoring will include verification of consent, adherence to protocol and reporting of adverse events. No on-site audits are anticipated unless concerns arise.

Research ethics approval (SPIRIT 30)

The study protocol, informed consent form and study materials have received approval from the Parkway Independent Ethics Committee (ref PIEC/2024/041, approved 18/06/2025). Any modifications will be submitted for ethics review prior to implementation.

Protocol amendments (SPIRIT 31)

All substantial protocol amendments (e.g., changes to eligibility criteria, outcomes, analyses) will be reviewed and approved by the relevant IRBs prior to implementation. Updates will also be made in the trial registry (ISRCTN12391932) and communicated to study sites, funders and participants as appropriate. Minor administrative amendments (e.g., corrections of typographical errors) will be documented in the trial master file.

Consent or assent (SPIRIT 32a-32b)

Informed consent

Written informed consent will be obtained from all participants prior to any study procedures. Trained research staff at the Active Ageing Centres will explain the purpose, procedures, risks and potential benefits of the study using a standardised information

sheet. Consent will be obtained in English, Mandarin, or local dialects, depending on participant preference. Adequate time will be provided for questions. Only participants providing signed consent will be enrolled.

Additional consent provisions

Consent will cover the collection and use of self-report data, wearable device-derived light and activity data, cognitive performance results and dried blood spot samples. Participants will also be asked for permission for their anonymised data to be used in future ancillary studies and for sharing under open-access conditions (CC-BY). No biological samples will be stored beyond the planned vitamin D analyses.

Confidentiality (SPIRIT 33)

Participant confidentiality will be preserved throughout the trial. Personal identifiers (e.g. name, contact details) will be collected separately from research data and stored in encrypted, password-protected files accessible only to authorised study staff. Each participant will be assigned a unique study ID, which will be used for all data collection and analysis.

Wearable device and app data will be transmitted securely to servers at TUMCREATE, where they will be encrypted and stored in compliance with the Singapore Personal Data Protection Act. All data shared with collaborators or made publicly available will be fully anonymised. Data will be retained for a minimum of 10 years following study completion.

Ancillary and post-trial care (SPIRIT 34)

As the intervention involves a digital health app and wearable devices, no specific ancillary or post-trial medical care is anticipated. Any discomfort related to device wear (e.g. skin irritation) will be addressed by study staff. Participants will be covered by institutional insurance policies for study-related harm, in accordance with local regulations.

No compensation is planned for non-study-related health events. Participants will receive a lay summary of the study findings at trial completion.

Open Science

Trial registration (SPIRIT 4)

This trial is registered with the International Standard Randomised Controlled Trial Number (ISRCTN) registry under identifier ISRCTN12391932. The registration was completed on 5 September 2025 and full details are publicly available via the ISRCTN website.

Protocol and statistical analysis plan (SPIRIT 5)

The full trial protocol will be published in *BMJ Open*. Any protocol amendments will be updated in the ISRCTN record to ensure accuracy and transparency. A separate statistical analysis plan will be finalised before database lock and will be made openly available on the Open Science Framework (OSF). This approach ensures that analytical procedures are defined in advance and can be independently scrutinised.

Data sharing (SPIRIT 6)

Upon completion of the trial and publication of the primary outcomes, anonymised participant-level data, the accompanying data dictionary, statistical code and all supporting documentation will be made available through the Open Science Framework. Data will be released under a CC-BY license, allowing unrestricted reuse with appropriate attribution. Shared materials will include de-identified data on light exposure, sleep, mood, cognition and vitamin D status, along with the relevant analytical scripts written in R and Python and documentation associated with the intervention. No application process will be required to access the dataset.

Funding and conflicts of interest (SPIRIT 7a-7b)

This research is funded by the National Research Foundation Singapore through the programme *Optimising environmental light exposure at scale to support eye and brain development and health across the lifespan* (LightSPAN), reference NRF2022-THE004-0002.

M.S. declares the following potential conflicts of interest in the past five years (2021-2025). **Academic roles:** Member of the Board of Directors, *Society of Light, Rhythms, and Circadian Health (SLRCH)*; Chair of *Joint Technical Committee 20 (JTC20)* of the *International Commission on Illumination (CIE)*; Member of the *Daylight Academy*; Chair of *Research Data Alliance Working Group Optical Radiation and Visual Experience Data*. **Remunerated roles:** Speaker of the Steering Committee of the *Daylight Academy*; Ad-hoc reviewer for the *Health and Digital Executive Agency* of the *European Commission*; Ad-hoc reviewer for the *Swedish Research Council*; Associate Editor for *LEUKOS*, journal of the *Illuminating Engineering Society*; Examiner, *University of Manchester*; Examiner, *Flinders University*; Examiner, *University of Southern Norway*. **Funding:** Received research funding and support from the *Max Planck Society*, *Max Planck Foundation*, *Max Planck Innovation*, *Technical University of Munich*, *Wellcome Trust*, *National Research Foundation Singapore*, *European Partnership on Metrology*, *VELUX Foundation*, *Bayerisch-Tschechische Hochschulagentur (BTHA)*, *BayFrance (Bayerisch-Französisches Hochschulzentrum)*, *BayFOR (Bayerische Forschungsallianz)*, and *Reality Labs Research*. **Honoraria for talks:** Received honoraria from the *ISGlobal*, *Research Foundation of the City University of New York* and the *Stadt Ebersberg, Museum Wald und Umwelt*. **Travel reimbursements**: *Daimler und Benz Stiftung*. **Patents:** Named on European Patent Application EP23159999.4A ("*System and method for corneal-plane physiologically-relevant light logging with an application to personalized light interventions related to health and well-being*"). With the exception of the funding source supporting this work, M.S. declares no influence of the disclosed roles or relationships on the work presented herein. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

The remaining authors declare no conflicts of interest.

Dissemination policy (SPIRIT 8)

The findings of this study will be primarily disseminated through scientific channels. Results will be published in peer-reviewed open access journals and preprints will be deposited on servers such as medRxiv to allow rapid access by the research community. In addition, anonymised participant-level data, statistical code and supporting documentation will be deposited in an open repository to ensure transparency and facilitate secondary analyses. Authorship will follow ICMJE guidelines and no professional medical writers will be involved in the preparation of manuscripts.

Structured summary (1b)

Item	Details
Primary registry and trial identifying number	ISRCTN12391932
Date of registration in primary registry	5 September 2025
Secondary identifying numbers	NRF2022-THE004-0002 (Funding reference)
Source(s) of monetary or material support	National Research Foundation, Prime Minister's Office, Singapore, under the Campus for Research Excellence and Technological Enterprise (CREATE) programme
Primary sponsor	TUM CREATE LTD, Singapore
Secondary sponsor(s)	Not applicable
Contact for public queries	Prof. Dr. Manuel Spitschan, TUM CREATE LTD, Singapore. Email: manuel.spitschan@tum-create.edu.sg
Contact for scientific queries	Prof. Dr. Manuel Spitschan, TUM CREATE LTD, Singapore. Email: manuel.spitschan@tum-create.edu.sg
Public title	Promoting healthy light exposure in older adults through a mobile health intervention in Singapore
Scientific title	A randomised, double-blind trial of a chronotherapeutic mHealth behaviour change intervention to optimise light exposure among older adults aged ≥60 years in Singapore (LightSPAN)
Countries of recruitment	Singapore
Health condition(s) or problem(s) studied	Circadian misalignment, poor sleep quality, mood disturbances, cognitive decline in older adults
Intervention(s)	Intervention group: LightUP smartphone application (with active behavioural features: feedback, reminders, goal-setting) + wearable light and activity monitoring. Comparator group: Placebo version of LightUP app (identical in appearance, without active behavioural features) + same monitoring devices.
Key inclusion criteria	– Age ≥ 60 years – Community-dwelling in Singapore – Owns a smartphone compatible with the LightUP app – Able to provide informed consent
Key exclusion criteria	– Severe visual impairment preventing use of devices – Cognitive impairment limiting app engagement – Current participation in another intervention trial affecting light exposure or sleep

Study type	Interventional, randomized, double-blind, placebo-controlled, parallel-group trial
Date of first enrolment	18 August 2025
Target sample size	90 participants
Recruitment status	Ongoing
Primary outcome(s)	The effectiveness of the LightUP app in improving light exposure behaviour in older adults, measured using data collected from the ActLumus light logger over the 4-week baseline period, the 12-week intervention period and the 2-week follow-up monitoring period Daily time above 250 lx melanopic equivalent daylight illuminance (minutes/day) during daytime, measured using the ActLumus light logger over the 12-week intervention, corrected to baseline and analysed with generalized linear mixed models, as well as long-term differences, assessed in the follow-up monitoring period relative to baseline
Key secondary outcomes	1. Sleep parameters (total sleep time, sleep efficiency, sleep onset latency, wake after sleep onset) measured using the Garmin Vivosmart 5 actigraphy and sleep diaries continuously over the study period. 2. Sleep quality measured using the Pittsburgh Sleep Quality Index (PSQI) at baseline (week 4), mid-point (week 10), endpoint (week 16) and follow-up (week 28). 3. Circadian rest-activity rhythms (interdaily stability, intradaily variability, relative amplitude) measured continuously using Garmin data over the study period. 3. Mood states measured using the Brief Mood Introspection Scale (BMIS) at baseline (week 4), mid-point (week 10), endpoint (week 16) and follow-up (week 28). 4. Daily mood ratings measured using the Single-Item Mood Scale (SIMS) throughout the study period. 5. Weekly mood ratings measured using the Visual Analogue Mood Scale (VAMS) over the 12-week intervention period. 6. Cognitive performance measured using the NIH Toolbox at baseline (week 4), mid-point (week 10), endpoint (week 16) and follow-up (week 28), including Dimensional Change Card Sort, Flanker Inhibitory Control and Attention, Oral Symbol Digit, Picture Sequence Memory Form A or B, Rey Auditory Verbal Learning, Rey Auditory Verbal Learning Delay and Pattern Comparison Processing Speed Test. 7. Frailty measured at baseline (week 4), mid-point (week 10), endpoint (week 16) and follow-up (week 28) using five criteria: unintentional weight loss, exhaustion identified with two items from the Centre for Epidemiologic Studies for Depression Scale (CES-D), low physical activity assessed with the Physical Activity Scale for the Elderly (PASE), slowness assessed with the 5-meter walking time test and weakness assessed with dominant hand grip strength. 8. Physical activity (daily step count, moderate-to-vigorous

activity, sedentary behaviour) measured continuously using Garmin data throughout the study period and PASE.

9. Body composition (weight, height, body fat percentage, muscle mass, bone mass, body mass index) measured using standard procedures at baseline (week 4), mid-point (week 10), endpoint (week 16) and follow-up (week 28).

10. Vitamin D status measured using 25(OH)D concentration from dried blood spot (DBS) samples and standard procedures at baseline (week 4), mid-point (week 10), endpoint (week 16) and follow-up (week 28).

11. Usability of the LightUP app measured using the mHealth App Usability Questionnaire (MAUQ) at endpoint (week 16).

12. Acceptability of the LightUP app measured using an adapted Technology Acceptance Model (TAM) questionnaire at endpoint (week 16).

13. Acceptability of wearable devices measured using an adapted Technology Acceptance Model (TAM) questionnaire at endpoint (week 16).

Trial design	Randomized (1:1), double-blind, placebo-controlled, parallel-group trial with 12-week intervention period and follow-up assessments
Data sharing statement	De-identified individual participant data and metadata will be made available upon reasonable request, in line with institutional and ethical guidelines

Protocol version

Protocol version (2)

25 March 2025, v1.0.0

Roles and responsibilities

Protocol contributors (3a)

M.S. (Principal Investigator, TUMCREATED Ltd.) conceived of the study and leads the trial. R.R.M., Z.A.A. and D.D.V. led and or contributed to study conception, methods development and protocol drafting. D.D.V. additionally led the research software engineering. All contributors participated in refining the study protocol and approved the final version.

Trial sponsor (3b)

The sponsor of this trial is:
TUM CREATE LTD
1 Create Way, #10-02 CREATE Tower
Singapore 138602
Phone: +65 6601 4015
Fax: +65 6694 0062
Website: **www.tum-create.edu.sg**
Contact person: Prof. Dr. Manuel Spitschan
Email: manuel.spitschan@tum-create.edu.sg

Role of sponsor and funders (3c)

Sponsor: TUM CREATE LTD serves as the sponsor of this trial. The sponsor is responsible for ensuring that the study is conducted in accordance with applicable regulatory and ethical requirements, including oversight of trial management, monitoring and quality assurance. The sponsor has no role in data collection, statistical analysis, interpretation of results, or publication decisions, which remain the responsibility of the investigators.

Funder: This research is supported by the National Research Foundation, Prime Minister's Office, Singapore, under its Campus for Research Excellence and Technological Enterprise (CREATE) programme (NRF2022-THE004-0002). The funders have no role in study design, data collection and analysis, interpretation of results, the decision to publish, or manuscript preparation.

Oversight committees and groups (3d)

Coordinating centre: The coordinating centre for this trial is TUM CREATE LTD, Singapore. The trial will be overseen by the Principal Investigator (Prof. Dr. Manuel Spitschan) together with the study management team based at TUM CREATE.

Trial management and oversight committees: Day-to-day trial management is carried out by the study team at TUM CREATE. Oversight is provided by the Principal Investigator, who is responsible for ensuring adherence to the protocol, regulatory compliance and ethical conduct. The study team meets regularly to review recruitment, progress, data quality and participant safety.

Data management team: Data are collected and managed by the research team at TUM CREATE using REDCap and secure institutional servers. All personal data are pseudonymised. Device data (ActLumus, Garmin Vivosmart 5, LightUP app) are managed through secure cloud-based platforms (Condor Cloud, Fitrockr, Google Firestore) and

732 subsequently stored on TUM CREATE servers. Statistical analysis will be conducted by
733 the designated data analysts on the study team.
734

Statements

Authors contributions

Conceptualization: RRM, ZAA, DDV, MS
Methodology: RRM, ZAA, DDV, JZ, MS
Software: DDV
Validation: –
Formal analysis: JZ
Investigation: RRM, ZAA, DDV, MS
Resources: –
Data curation: –
Writing – original draft: RRM, ZAA, DDV, MS
Writing – review & editing: RRM, ZAA, DDV, JZ, MS
Visualization: –
Supervision: MS
Project administration: RRM, MS
Funding acquisition: MS

Funding statement

This research is funded by the National Research Foundation Singapore through the programme *Optimising environmental light exposure at scale to support eye and brain development and health across the lifespan* (LightSPAN), reference NRF2022-THE004-0002. JZ's position was financially supported by MeLiDos. The project (22NRM05 MeLiDos) has received funding from the European Partnership on Metrology, co-financed by the European Union's Horizon Europe Research and Innovation Programme and by the Participating States. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or EURAMET. Neither the European Union nor the granting authority can be held responsible for them.

Competing interests

M.S. declares the following potential conflicts of interest in the past five years (2021–2025). **Academic roles:** Member of the Board of Directors, *Society of Light, Rhythms and Circadian Health (SLRCH)*; Chair of *Joint Technical Committee 20 (JTC20)* of the *International Commission on Illumination (CIE)*; Member of the *Daylight Academy*; Chair of *Research Data Alliance Working Group Optical Radiation and Visual Experience Data*. **Remunerated roles:** Speaker of the Steering Committee of the *Daylight Academy*; Ad-hoc reviewer for the *Health and Digital Executive Agency* of the *European Commission*; Ad-hoc reviewer for the *Swedish Research Council*; Associate Editor for *LEUKOS*, journal of the *Illuminating Engineering Society*; Examiner, *University of Manchester*; Examiner, *Flinders University*; Examiner, *University of Southern Norway*. **Funding:** Received research funding and support from the *Max Planck Society*, *Max Planck Foundation*, *Max Planck Innovation*, *Technical University of Munich*, *Wellcome Trust*, *National Research Foundation Singapore*, *European Partnership on Metrology*, *VELUX Foundation*, *Bayerisch-Tschechische Hochschulagentur (BTHA)*, *BayFrance (Bayerisch-Französisches Hochschulzentrum)*, *BayFOR (Bayerische Forschungsallianz)* and *Reality Labs Research*. **Honoraria for talks:** Received honoraria from the *ISGlobal*, *Research Foundation of the City University of New York* and the *Stadt Ebersberg, Museum Wald und Umwelt*. **Travel reimbursements**: *Daimler und Benz Stiftung*. **Patents:** Named on European Patent Application EP23159999.4A ("*System and method for corneal-plane physiologically-relevant light logging with an application to personalized light interventions related to health and well-being*"). With the exception of the funding source supporting this work,

References

1. Blume C, Garbazza C, Spitschan M. Effects of light on human circadian rhythms, sleep and mood. *Somnologie (Berl)* 2019;23(3):147-56. doi: 10.1007/s11818-019-00215-x [published Online First: 20190820]
2. Burns AC, Windred DP, Rutter MK, et al. Day and night light exposure are associated with psychiatric disorders: an objective light study in >85,000 people. *Nature Mental Health* 2023;1(11):853-62. doi: 10.1038/s44220-023-00135-8
3. Windred DP, Burns AC, Lane JM, et al. Brighter nights and darker days predict higher mortality risk: A prospective analysis of personal light exposure in >88,000 individuals. *Proc Natl Acad Sci U S A* 2024;121(43):e2405924121. doi: 10.1073/pnas.2405924121 [published Online First: 20241015]
4. Windred DP, Burns AC, Rutter MK, et al. Personal light exposure patterns and incidence of type 2 diabetes: analysis of 13 million hours of light sensor data and 670,000 person-years of prospective observation. *Lancet Reg Health Eur* 2024;42:100943. doi: 10.1016/j.lanepe.2024.100943 [published Online First: 20240605]
5. Lazar R, Degen J, Fiechter AS, et al. Regulation of pupil size in natural vision across the human lifespan. *R Soc Open Sci* 2024;11(6):191613. doi: 10.1098/rsos.191613 [published Online First: 20240619]
6. Verma AK, Singh S, Rizvi SI. Aging, circadian disruption and neurodegeneration: Interesting interplay. *Exp Gerontol* 2023;172:112076. doi: 10.1016/j.exger.2022.112076 [published Online First: 20221224]
7. Dev MK, Black AA, Cuda D, et al. Low Light Exposure and Physical Activity in Older Adults With and Without Age-Related Macular Degeneration. *Transl Vis Sci Technol* 2022;11(3):21. doi: 10.1167/tvst.11.3.21
8. Hood S, Amir S. The aging clock: circadian rhythms and later life. *J Clin Invest* 2017;127(2):437-46. doi: 10.1172/JCI90328 [published Online First: 20170201]
9. Lin JB, Tsubota K, Apte RS. A glimpse at the aging eye. *NPJ Aging Mech Dis* 2016;2:16003. doi: 10.1038/npjamd.2016.3 [published Online First: 20160310]
10. Duffy JF, Zitting KM, Chinoy ED. Aging and Circadian Rhythms. *Sleep Med Clin* 2015;10(4):423-34. doi: 10.1016/j.jsmc.2015.08.002 [published Online First: 20150915]
11. Owsley C. Aging and vision. *Vision Res* 2011;51(13):1610-22. doi: 10.1016/j.visres.2010.10.020 [published Online First: 20101023]
12. Van Someren EJ, Kessler A, Mirmiran M, et al. Indirect bright light improves circadian rest-activity rhythm disturbances in demented patients. *Biol Psychiatry* 1997;41(9):955-63. doi: 10.1016/S0006-3223(97)89928-3
13. Skjerve A, Bjorvatn B, Holsten F. Light therapy for behavioural and psychological symptoms of dementia. *Int J Geriatr Psychiatry* 2004;19(6):516-22. doi: 10.1002/gps.1087
14. Forbes D, Blake CM, Thiessen EJ, et al. Light therapy for improving cognition, activities of daily living, sleep, challenging behaviour, and psychiatric disturbances in dementia. *Cochrane Database Syst Rev* 2014;2014(2):CD003946. doi: 10.1002/14651858.CD003946.pub4 [published Online First: 20140226]
15. Faulkner SM, Dijk DJ, Drake RJ, et al. Adherence and acceptability of light therapies to improve sleep in intrinsic circadian rhythm sleep disorders and neuropsychiatric illness: a systematic review. *Sleep Health* 2020;6(5):690-701. doi: 10.1016/j.sleh.2020.01.014 [published Online First: 20200312]
16. Biller AM, Balakrishnan P, Spitschan M. Behavioural determinants of physiologically-relevant light exposure. *Commun Psychol* 2024;2(1):114. doi: 10.1038/s44271-024-00159-5 [published Online First: 20241129]

17. Siraji MA, Lazar RR, van Duijnhoven J, et al. An inventory of human light exposure behaviour. *Sci Rep* 2023;13(1):22151. doi: 10.1038/s41598-023-48241-y [published Online First: 20231213]

18. Alkaff ZA, Murukesu RR, Del Villar D, et al. Protocol for a co-design study for the development of a chronotherapeutic mobile health behaviour change intervention targeting light exposure among older adults. *F1000Res* 2024;13:1356. doi: 10.12688/f1000research.157814.2 [published Online First: 20250725]

19. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. *Gerontologist* 1969;9(3):179-86.

20. Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. *J Am Geriatr Soc* 2005;53(4):695-9. doi: 10.1111/j.1532-5415.2005.53221.x

21. Yesavage JA, Sheikh JI. Geriatric Depression Scale (GDS). *Clinical Gerontologist* 2008;5(1-2):165-73. doi: 10.1300/J018v05n01_09

22. Buysse DJ, Reynolds CF, 3rd, Monk TH, et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. *Psychiatry Res* 1989;28(2):193-213. doi: 10.1016/0165-1781(89)90047-4

23. Mayer JD, Gaschke YN. Brief Mood Introspection Scale. *APA PsycTests* 1988 doi: 10.1037/t06259-000

24. van Rijsbergen GD, Bockting CL, Berking M, et al. Can a one-item mood scale do the trick? Predicting relapse over 5.5-years in recurrent depression. *PLoS One* 2012;7(10):e46796. doi: 10.1371/journal.pone.0046796 [published Online First: 20121003]

25. Gershon RC, Wagster MV, Hendrie HC, et al. NIH toolbox for assessment of neurological and behavioral function. *Neurology* 2013;80(11 Suppl 3):S2-6. doi: 10.1212/WNL.0b013e3182872e5f

26. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. *J Gerontol A Biol Sci Med Sci* 2001;56(3):M146-56. doi: 10.1093/gerona/56.3.m146

27. Zhou L, Bao J, Setiawan IMA, et al. The mHealth App Usability Questionnaire (MAUQ): Development and Validation Study. *JMIR Mhealth Uhealth* 2019;7(4):e11500. doi: 10.2196/11500 [published Online First: 20190411]

28. Xie Z, Kalun Or C. Acceptance of mHealth by Elderly Adults: A Path Analysis. *Proceedings of the Human Factors and Ergonomics Society Annual Meeting* 2021;64(1):755-59. doi: 10.1177/1071181320641174

29. Eysenbach G. The law of attrition. *J Med Internet Res* 2005;7(1):e11. doi: 10.2196/jmir.7.1.e11 [published Online First: 20050331]

30. Milne-Ives M, Lam C, De Cock C, et al. Mobile Apps for Health Behavior Change in Physical Activity, Diet, Drug and Alcohol Use, and Mental Health: Systematic Review. *JMIR Mhealth Uhealth* 2020;8(3):e17046. doi: 10.2196/17046 [published Online First: 20200318]

31. Zauner J, Hartmeyer S, Spitschan M. LightLogR: Reproducible analysis of personal light exposure data. *J Open Source Softw* 2025;10(107):7601. doi: 10.21105/joss.07601

32. Wickham H, Averick M, Bryan J, et al. Welcome to the Tidyverse. *Journal of Open Source Software* 2019;4(43) doi: 10.21105/joss.01686

33. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. *Journal of the Royal Statistical Society Series B: Statistical Methodology* 1995;57(1):289-300. doi: 10.1111/j.2517-6161.1995.tb02031.x

34. Barr DJ, Levy R, Scheepers C, et al. Random effects structure for confirmatory
hypothesis testing: Keep it maximal. *J Mem Lang* 2013;68(3) doi:
10.1016/j.jml.2012.11.001
35. Hastie T, Tibshirani R. Generalized Additive Models. *Statistical Science* 1986;1(3) doi:
10.1214/ss/1177013604
36. Zauner J, Guidolin C, Spitschan M. How to Deal With Darkness: Modeling and
Visualization of Zero-Inflated Personal Light Exposure Data on a Logarithmic Scale.
J Biol Rhythms 2025:7487304251336624. doi: 10.1177/07487304251336624
[published Online First: 20250628]
901